Why Anavex Life Sciences Corp.’s (AVXL) Stock Is Up 6.00%
As of Tuesday, October 20, Anavex Life Sciences Corp.’s AVXL share price has surged by 6.00%, which has investors questioning if this is right time to sell.Michael Rose
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Anavex Life Sciences Corp. operates as a biopharmaceutical company. It engages in developing innovative treatments for Alzheimer’s disease, Parkinson’s disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, pain, and various types of cancer. Its lead drug candidate, ANAVEX 2-73 (blarcamesine), which has completed a Phase 2a and a Phase 2b/3 clinical trial for Alzheimer's disease; a Phase 2 proof-of-concept study in Parkinson's disease dementia; and a Phase 2 and a Phase 3 study in adult patients and one Phase 2/3 study in pediatric patients with Rett syndrome. Its ANAVEX 2-73 is an orally available drug designed to restore cellular homeostasis by targeting SIGMAR1 and muscarinic receptors, as well as exhibits anticonvulsant, anti-amnesic, neuroprotective, and anti-depressant properties in animal models indicating its potential to treat additional CNS disorders, including epilepsy. The company’s ANAVEX 3-71 that targets SIGMAR1 and M1 muscarinic receptors, which is a clinical stage drug candidate demonstrating disease-modifying activity against Alzheimer's disease in transgenic (3xTg-AD) mice, such as cognitive deficits, amyloid, and tau pathologies. Anavex Life Sciences Corp. was incorporated in 2004 and is headquartered in New York, New York.
Commentary & Analysis
Why Anavex Life Sciences Corp.’s (AVXL) Stock Is Up 10.80%
As of Tuesday, October 20, Anavex Life Sciences Corp.’s AVXL share price has surged by 10.80%, which has investors questioning if this is right time to sell.Jenna Brashear
Why Anavex Life Sciences Corp.’s (AVXL) Stock Is Down 8.02%
As of Monday, October 19, Anavex Life Sciences Corp.’s AVXL share price has dipped by 8.02%, which has investors questioning if this is right time to buy.Jenna Brashear
Why Anavex Life Sciences Corp.’s (AVXL) Stock Is Down 10.22%
As of Friday, October 16, Anavex Life Sciences Corp.’s AVXL share price has dipped by 10.22%, which has investors questioning if this is right time to buy.Michael Rose
Why Anavex Life Sciences Corp.’s (AVXL) Stock Is Down 5.52%
As of Friday, October 09, Anavex Life Sciences Corp.’s AVXL share price has dipped by 5.52%, which has investors questioning if this is right time to buy.Jenna Brashear
Financial Summary
| Share Statistics | AVXL | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $126.1 | $228.7 | 24% |
|
| Shares Out (Mil) | 92.9 | 53.9 | 61% |
|
| Institutional Ownership | 92.8% | 92.9% | 62% |
|
| Float (Mil) | 89.8 | 42.1 | 58% |
|
| Beta | 1.14 | 0.95 | 67% |
|
| Avg Daily Volume (000s) | 1,420 | 574 | 76% |
|
| Price Change (52-week) |
(85.5%) | 47.3% | 7% |
|
| Growth | AVXL | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.6% | na |
|
| Net Income (5yr) | (12.0%) | (10.1%) | 27% |
|
| EPS (5yr) | (3.8%) | 15.8% | 26 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | (37.5%) | (15.7%) | 13% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | AVXL | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $37 | na |
|
| Net Income (TTM) (Mil) | ($13) | ($44) | 27% |
|
| EPS (TTM) | ($0.145) | ($1.500) | 34% |
|
| Operating Cash Flow (TTM) (Mil) | ($29) | ($33) | 13% |
|
| Net Cash Flow (TTM) (Mil) | na | $2 | na |
|
| Long-Term Debt (Q1) (Mil) | $0 | $4 | 0% |
|
| Enterprise Value (Q1) (Mil) | $106 | $177 | 22% |
|
| Valuation | AVXL | Industry Median |
Percentile (All Stocks) |
|
| P/B | 1.12 | 2.24 | 30% |
|
| P/E | na | 20.0 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | AVXL | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 66.9% | na |
|
| Net Margin | na | (73.7%) | na |
|
| ROA | (11.7%) | (47.0%) | 24% |
|
| ROE | (12.8%) | (54.1%) | 26% |
|
| Liabilities to Assets | 6.4% | 29.1% | 3% |
|
| F-Score | 2 | 2 | 7% |
|
Anavex Life Sciences Corp. did not pass any screens on 10/21/2026.
